13 results about "Clopidogrel" patented technology

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

The disclosure discloses a method for treating a plasma sample containing (7aS,2′S)-2-oxo-clopidogrel and a method for determining the same, which belongs to the technical field of pharmaceutical analysis and solves the problem in the prior art that there is not yet a method for determining the concentration of (7aS,2′S)-2-oxo-clopidogrel in plasma. The method for treating a plasma sample containing (7aS,2′S)-2-oxo-clopidogrel comprises: taking whole blood containing (7aS,2′S)-2-oxo-clopidogrel, adding a reducing agent solution and collecting plasma. The method for determining (7aS,2′S)-2-oxo-clopidogrel in plasma according to the disclosure uses the treatment method as described above to treat a sample to be determined, and includes the following steps: S1. Whole blood treatment: taking whole blood, adding a reducing agent solution, centrifuging, and collecting plasma; S2. Plasma sample pre-treatment: adding a protein precipitant and an internal standard working solution to the plasma, vortexing and then centrifuging, and taking the supernatant; S3. LC / MS / MS determination. The method of the disclosure is simple, easy to operate, and has good stability, specificity and sensitivity, and accurate determination results.

The invention discloses a method for producing a clopidogrel intermediate through biological catalysis chiral resolution, which comprises the following steps: screening an esterase mutant capable of efficiently resolving the clopidogrel intermediate (R, S)-2-(2-chlorphenyl)-2-(2-thiophene ethylamino) methyl acetate through molecular modification to obtain (S)-2-(2-chlorphenyl)-2-(2-thiophene ethylamino) methyl acetate; according to the present invention, the biocatalysis activity and the stereoselectivity are high, the reaction efficiency is improved, the position of the biocatalysis step in the whole synthesis route is beneficial to the improvement of the efficiency of other chemical steps, the overall conversion rate, the enantiomer excess value and the product purity, and the production cost can be significantly reduced. In addition, the method also has the common advantages of enzymatic synthesis, such as simplicity and convenience in implementation and operation, greenness and environmental protection, easiness in product separation and the like.

The invention relates to the technical field of drug analysis and detection, in particular to a method for detecting specific impurities in a compound preparation clopidogrel aspirin tablet. The method comprises the following steps: mixing a compound preparation clopidogrel aspirin powder with an extraction solvent, carrying out ultrasonic extraction, filtering, and taking supernate to prepare a test solution; a test solution is detected by adopting a high performance liquid chromatography, and chromatographic conditions are as follows: a chromatographic column is an octadecyl bonded silica gel chromatographic column; a mobile phase A is an ion pair buffer salt solution; and the mobile phase B is acetonitrile. According to the method disclosed by the invention, effective separation of seven specific clopidogrel impurities and six specific aspirin impurities can be realized, and the responsivity is relatively good.

The invention discloses a clopidogrel aspirin tablet and a preparation method thereof, the clopidogrel aspirin tablet is prepared by tabletting an aspirin layer and a clopidogrel layer, the aspirin layer is composed of an aspirin tablet core, two isolation layers and an enteric-coated layer inserted between the two isolation layers, and the dosage of talcum powder is reduced to be less than 40% of the total weight of an enteric-coated material. According to the clopidogrel aspirin tablet and the preparation method thereof, on the premise that the coating process is smooth and free of precipitation and flocculation phenomena, the prepared clopidogrel aspirin tablet has good pressure resistance and acid resistance and good long-term dissolution stability by controlling the selection of a specific plasticizer (preferably polyethylene glycol 400) in the aspirin layer and optimizing the dosage, and the clopidogrel aspirin tablet is equivalent to an original reference preparation.

The invention relates to the field of molecular biology and biological medicine, and particularly discloses a synergistic effect of combined application of Metrnl protein and a clinical first-line therapeutic drug clopidogrel for treating thrombus, and the Metrnl protein has important significance in the field of thrombotic disease treatment. According to the invention, mice are divided into four groups: a solvent control group, a Metrnl proteome, a clopidogrel group and a drug combination group. A FeCl3 induced thrombus experiment shows that thrombus formation can be inhibited by independently using Metrnl protein and clopidogrel, the thrombus formation inhibition effect is stronger by combined medication, and a synergistic effect is achieved. In addition, in the aspect of untoward effects of bleeding, compared with a clopidogrel single drug group, the risk of bleeding of the drug combination group is not obviously increased. The metrnl protein and clopidogrel are combined to enhance the antithrombotic curative effect without increasing the adverse reaction of bleeding, so that the metrnl protein and clopidogrel have good treatment potential and safety.

The invention discloses a method for detecting impurities in clopidogrel aspirin tablets. Relates to the technical field of medicine. According to the detection method for the impurities in the clopidogrel aspirin tablets, the clopidogrel aspirin tablets are detected by adopting a high performance liquid chromatography, and the chromatographic conditions of the high performance liquid chromatography are as follows: a separation medium in a chromatographic column is octadecyl silica gel; the mobile phase comprises a sodium perchlorate buffer solution with the pH value of 2.0-3.0; the column temperature is less than 35 DEG C. According to the method for detecting the impurities in the clopidogrel and aspirin tablets, 13 impurities in a clopidogrel and aspirin tablet compound preparation can be detected at the same time.

The application provides a combined drug for improving embryo implantation efficiency of RIF patients and a screening method, and belongs to the technical field of embryo implantation. In order to solve the problem of how to screen a general drug combination on the basis of a large heterogeneous RIF population, the application locks 1119 kinds of drugs that may have a therapeutic effect in a large range through a six-step screening method combined with advanced RNA sequencing technology, and then further screens the drugs by using a highly simulated endometrial epithelial organoid and stromal cell model, tests the influence of the 1119 kinds of drugs on the activity of the endometrial epithelial organoid and stromal cell, and finally screens 7 kinds of effective drugs which can form a broad-spectrum drug with significant therapeutic effect on RIF in a combined form. The 7 kinds of effective drugs screened by the application are icotinib, fumaric acid propofol tenofovir tablets, clopidogrel, tizacat, osimertinib, venetoclax and rebastinib.

The invention discloses a clinical drug crowd reaction data arrangement and analysis system, which relates to the technical field of clinical drug crowd reaction data arrangement and comprises a data acquisition module, a data processing module, an arrangement module, a processing module and an analysis module. According to the method, the reactivity of the patient to clopidogrel can be accurately evaluated according to the multi-dimensional information of the patient by calculating the clopidogrel low reactivity index, a scientific basis is provided for timely adjusting a treatment scheme, the risk of adverse reactions such as bleeding is reduced, the risk degree of the adverse reactions can be calculated based on the multi-dimensional information of the patient, and the risk degree of the adverse reactions can be accurately evaluated according to the multi-dimensional information of the patient. The adverse reaction risk possibly occurring when the patient receives double-antibody treatment is predicted, a doctor can take preventive measures in advance, the adverse reaction occurrence rate of the patient is reduced, the treatment safety is improved, personalized pharmaceutical services can be provided according to the individual characteristics of the patient by calculating the medication evaluation index, and the clinical application prospect is wide. Therefore, individual requirements of the patient can be met, and the satisfaction degree and the treatment effect of the patient can be improved.

The invention discloses a pharmaceutical composition and application of the pharmaceutical composition in preparation of drugs for treating thrombotic diseases. The invention discovers that the composition formed by the dazoloxybenzene and the clopidogrel in the mass ratio of 1: 10-10: 1 has a remarkable antithrombotic effect, and the dazoloxybenzene and the clopidogrel generate a synergistic antithrombotic effect in the mass ratio of 1: 8-8: 1, so that an additional gain effect of 1 + 1 > 2 is achieved. Meanwhile, the composition formed by the dazoloxybenzene and the clopidogrel in a mass ratio of (1: 2)-(2: 1) can remarkably reduce the bleeding risk and has a synergistic effect. Therefore, the composition of the dazoloxybenzene and the clopidogrel, provided by the invention, has a prospect of being developed into an antithrombotic drug, and the bleeding risk is reduced while thrombus formation is inhibited.

The present invention provides a pharmaceutical composition comprising clopidogrel or pharmaceutically acceptable salts thereof; and tegoprazan or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention has an advantage of maintaining a medicinal effect of clopidogrel while preventing or treating a side effect of clopidogrel, i.e., gastrointestinal disorders.

The invention provides a combined medicine for improving the embryo implantation efficiency of RIF patients and a screening method, and belongs to the technical field of embryo implantation. In order to solve the problem of how to screen general drug combinations on the basis of a huge heterogeneity RIF group, 1119 drugs which possibly have treatment effects are locked in a large range through a six-step screening method in combination with an advanced RNA (Ribonucleic Acid) sequencing technology; the method comprises the following steps: selecting 1119 types of medicines, then further utilizing a highly simulated endometrial epithelium organ and interstitial cell model to screen medicines, testing the influence of the 1119 types of medicines on the activity of the endometrial epithelium organ and interstitial cell, and finally screening 7 types of effective medicines to form a broad-spectrum medicine with a remarkable curative effect on RIF through a combination form. The seven effective drugs screened by the invention are respectively icotinib, a propofol fumarate tenofovir tablet, clopidogrel, tizacarbox, osimertinib, Vinetogram and ribotinib.